Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Type: Poster Session

Time: Monday June 3, 8:00 AM to 11:00 AM

Location: Hall A

Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.

Sub-category:
Hodgkin Lymphoma

Category:
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Meeting:
2019 ASCO Annual Meeting

Abstract No:
7532

Poster Board Number:
Poster Session (Board #286)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 7532)

Author(s): David J. Straus, Monika Długosz-Danecka, Sergiy Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Kerry J. Savage, Piotr Smolewski, Nancy L. Bartlett, Andrea Gallamini, Jan Andrzej Walewski, Rod Ramchandren, Pier Luigi Zinzani, Joseph M. Connors, Hina Jolin, Rachael Liu, Keenan Fenton, Michelle Fanale, John A. Radford; Memorial Sloan Kettering Cancer Center, New York, NY; Department of Hematology, Jagiellonian University, Krakow, Poland; N.N. Petrov Scientific Reserch Institute of Oncology, St. Petersburg, Russia; University of Debrecen, Medical and Health Science Center, Debrecen, Hungary; Department of Advanced Biomedical Science, Napoli, Italy; Institute of Hematology and Transfusion Medicine, Department of Hematology, Centre of Postgraduate Medical Education, Warsaw, Poland; John Theurer Cancer Center, Hackensack, NJ; British Columbia Cancer Agency, Center for Lymphoid Cancer, Vancouver, BC, Canada; Medical University of Lodz, Lodz, Poland; Washington University School of Medicine in St. Louis and Siteman Cancer Center, St. Louis, MO; Research Innovation and Statistics, Antoine-Lacassagne Cancer Centre, Nice, France; Maria Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; Barbara Ann Karmanos Cancer Institute, Detroit, MI; Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy; British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, BC, Canada; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Millenium Pharmaceutics, a wholly owned Subsidiary of Takeda Pharmaceuticals, Inc., Cambridge, MA; Seattle Genetics, Inc., Bothell, WA; Seattle Genetics, Inc, Bothell, WA; Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

Abstract Disclosures

Abstract:

Background: The phase 3 ECHELON-1 study demonstrated that BV with AVD (A+AVD) was superior to ABVD for the frontline treatment of Stage 3/4 cHL. Maturing data from RATHL and SWOG S0816 show limitations to PET2-adapted strategies, including short and long-term toxicities in PET2+ patients (pts) switched to BEACOPP and still frequent relapse in PET2- pts. Pts in the RATHL trial with Stage 3/4 disease ≤60 yrs had a 3-yr PFS of 79.8% (82.1% PET2-); SWOG S0816 reported a 5-yr PFS of 74% (76% PET2-) in the same population. As an alternative to PET-adapted therapy, here we present a 3-year update of the ECHELON-1 study, including ITT PFS and outcomes by PET status. Methods: Pts with Stage 3/4 cHL were randomized 1:1 to receive up to six cycles of A+AVD (n=664) or ABVD (n=670). Interim PET scan after cycle 2 was conducted. All analyses of PFS are exploratory and per investigator assessment. Results: At a median follow-up of 37 months, analysis of PFS in the ITT population favors the A+AVD treatment arm (Table), with a 3-yr PFS of 83.1% for A+AVD vs 76.0% for ABVD; the 3-yr PFS for PET2- pts <60 yrs was 87.2% vs 81.0%, respectively. Trend toward benefit for PET2+ pts <60 yrs treated with A+AVD was also observed, with a 3-yr PFS of 69.2% vs 54.7% with ABVD. Data from prespecified subgroups and safety follow-up, including peripheral neuropathy, will be presented. Conclusions: Follow-up at 3-yrs demonstrates that frontline treatment of Stage 3/4 cHL with A+AVD provides a durable treatment benefit vs ABVD that is independent of PET2 status. While direct comparisons cannot be made, A+AVD compares favorably to PET-adapted strategies without requiring interim PET assessment, escalation of therapy, or bleomycin. Clinical trial information: NCT01712490

% (95% CI)A+AVD
n=664
ABVD
n=670
HR (95% CI)
p value
All pts (ITT)83.1 (79.9–85.9)76.0 (72.4–79.2)0.70 (0.55–0.90)
0.005
PET2-n=577n=5730.69 (0.52–0.91)
85.8 (82.6–88.5)79.5 (75.8–82.7)0.009
PET2+n=58n=630.59 (0.33–1.07)
67.7 (53.8–78.3)51.5 (38.2–63.4)0.077
Pts <60 yrsn=580n=5680.69 (0.52–0.91)
84.9 (81.6–87.7)77.8 (73.9–81.1)0.008
Pts <60 yrs,n=512n=4890.71 (0.51–0.98)
PET2-87.2 (83.9–89.9)81.0 (77.1–84.4)0.034
Pts <60 yrs,n=51n=540.60 (0.32–1.15)
PET2+69.2 (54.1–80.1)54.7 (40.0–67.2)0.117

 
Other Abstracts in this Sub-Category:

 

1. Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.

Meeting: 2019 ASCO Annual Meeting Abstract No: 7533 First Author: Hang Su
Category: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - Hodgkin Lymphoma

 

2. Circulating tumor DNA to predict response and resistance by anti-PD-1 therapy in Chinese relapsed/refractory classic Hodgkin lymphoma.

Meeting: 2019 ASCO Annual Meeting Abstract No: 7534 First Author: Hang Su
Category: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - Hodgkin Lymphoma

 

3. Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.

Meeting: 2019 ASCO Annual Meeting Abstract No: TPS7567 First Author: Christine Mauz-Körholz
Category: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - Hodgkin Lymphoma

 

More...